Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiogenesis inhibitors in lung cancer.
Kim ES, Herbst RS. Kim ES, et al. Curr Oncol Rep. 2002 Jul;4(4):325-33. doi: 10.1007/s11912-002-0008-0. Curr Oncol Rep. 2002. PMID: 12044242 Review.
Novel therapeutics for head and neck cancer.
Kim ES, Kies M, Herbst RS. Kim ES, et al. Curr Opin Oncol. 2002 May;14(3):334-42. doi: 10.1097/00001622-200205000-00014. Curr Opin Oncol. 2002. PMID: 11981281 Review.
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Herbst RS, et al. Among authors: kim es. J Clin Oncol. 2005 Apr 10;23(11):2544-55. doi: 10.1200/JCO.2005.02.477. Epub 2005 Mar 7. J Clin Oncol. 2005. PMID: 15753462 Clinical Trial.
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Tran HT, Zinner RG, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Tran HT, et al. Invest New Drugs. 2011 Jun;29(3):499-505. doi: 10.1007/s10637-009-9380-z. Epub 2010 Jan 22. Invest New Drugs. 2011. PMID: 20094773 Clinical Trial.
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Tsao AS, et al. Among authors: kim e. J Thorac Oncol. 2013 May;8(5):658-61. doi: 10.1097/JTO.0b013e31828d08ae. J Thorac Oncol. 2013. PMID: 23584298 Free PMC article. Clinical Trial.
23,684 results
You have reached the last available page of results. Please see the User Guide for more information.